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RODRiGUEZ-MARTtiN, E., A. M. VALENCIA, B. COLAS, C. GARCiA-ESCRIBANO, M. RODtiGUEZ-PUY0L.C. SU- 
SIN1 AND E. ARILLA. Somatostatin binding capacity, guanylafe cyclase and tyrosine phosphatase activities during pancreatic 
proliferation in the nzt induced by gastrecromy. PEPTIDES 16(8) 1461- 1467, 1995.-Gastrectomy increased pancreatic growth 
and this effect was associated with an increase in the number of somatostatin-14 (SS) receptors (146% of control) without altering 
their affinity. SS increased guanylate cyclase activity twofold in pancreatic acinar membranes from gastrectomized rats. The 
gastrectomy decreased pancreatic SS-like immunoreactivity (SS-LI) content (55% of control levels) and tyrosine phosphatase 
activity (74% of contial levels). Administration of proglumide (20 mgkg, IP), a gastrin/cholecystokinin (CCK) receptor antagonist, 
suppressed the inhibitory effect of gastrectomy on basal tyrosine phosphatase activity and SS-LI content, which returned to control 
levels. Furthermore, proglumide suppressed the increase of the number of SS receptors and of SS-stimulated guanylate cyclase 
activity induced by gastrectomy. All this suggests that pancreatic acinar cell growth is associated with upregulation of SS receptors, 
which could represent amechanism promoted by the cell to negatively regulate the mitogenic activity of pancreatic growth factors 
such as CCK. In addition, the results also suggest that the negative regulation of tyrosine phosphatase activity may be important 
in the events involved in the pancreatic hyperplasia observed after gastrectomy. 
Gastrectomy Guanylate cyclase Somatostatin receptors 
Somatostatin like-immunoreactivity Rat 
Pancreatic acinar membranes 
SOMATOSTATIN-14 (SSJ is a tetradecapeptide synthesized in 
endocrine D cells that is widely distributed in the gastrointestinal 
tract (4,21) and is known to inhibit the stimulatory effects of 
various secretagogues on a number of cell functions, including 
endocrine and exocrine functions of the pancreas (53). More re- 
cently, SS analogues have been shown to inhibit the growth of 
normal and tumoral cells (:23,45). In the pancreas, SS inhibited 
normal (23,45) and caerulein-stimulated pancreatic growth 
(31,42), whereas the neutralization of the endogenous SS with 
antiserum amplified the growth-stimulating effect of caerulein 
(31). These observations have led to the suggestion that this pep- 
tide has a physiologically important function in the regulation of 
normal cell growth and that it might be a negative regulator of 
pancreatic acinar cell proliferation in vivo. SS exerts its physio- 
logical actions by interacting with membrane-bound receptors 
(48,58), which are coupled to adenylate cyclase (43), K’ chan- 
nels (61), voltage-dependent Ca*’ channels (62), and tyrosine 
phosphatase (12). In addition, several authors have shown that 
SS increases the guanylate cyclase activity in several tissues 
(11,17,54). Recent studies argue that, in contrast to cyclic AMP 
(57), cyclic GMP has a role in the antiproliferative effect of 
ss (41). 
One strong stimulant of exocrine pancreatic growth in the rat 
is a total gastrectomy, which results in acinar cell hyperplasia 2 
weeks after the intervention (10). To determine whether SS is 
involved in exocrine pancreas growth responses in vivo, we mea- 
sured the status of SS binding and pancreatic somatostatin-like 
immunoreactivity (SS-LI) content in control pancreas and during 
pancreatic proliferation 2 weeks after gastrectomy in rats. This 
study also examines the basal activity of the guanylate cyclase 
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system as well as the stimulatory effect of SS on this enzyme 
activity in these membranes. Cholecystokinin (CCK) is the major 
humoral candidate in promoting postgastrectomy pancreatic hy- 
perplasia (9,29). Proglumide, an antagonist of the receptors of 
the gastrin/CCK peptide family (37). was used to evaluate 
whether the effects of gastrectomy on the pancreatic somatosta- 
tinergic system involved the activation of gastrin/CCK receptors. 
Protein tyrosine phosphatases have been reported to play a cru- 
cial role in cellular processes involving protein phosphorylation 
such as growth and differentiation (60). The fact that tyrosine 
phosphatase activity is stimulated by growth factor inhibitors, 
like SS (50) and transforming growth factor p (TGF-P) (20), and 
by differentiating agents (5 153) that inhibit cell growth suggests 
an inverse relationship between tyrosine phosphatase activity and 
cell growth. Therefore, protein tyrosine phosphatase activity was 
also determined in the membrane preparations previously cited. 
Preparation of Rat Pancreatic Acinar Membranes 
as a standard. 
Dispersed pancreatic acini were obtained from male Wistar 
rats after enzymatic degradation of the pancreas with 0.2 units of 
collagenase/ml in an oxygenated Krebs-Ringer medium as de- 
scribed by Amsterdam et al. (2). After washing by sedimentation, 
acini were transferred to 0.3 M sucrose, 0.03% soybean trypsin 
inhibitor, 0.1 mM PMSF, and 1 mM benzamidine (buffer A). In 
this buffer, the acini were homogenized at 4°C by use of a Potter 
homogenizer. After centrifugation at 600 X g for 5 min at 4”C, 
the supematant was resuspended in buffer A and centrifuged at 
100,000 x g in a TLA 100.3 rotor for 1 h. The supematant was 
discarded and the pellet was resuspended in 50 mM Tris-HCl, 
pH 7, 0.5 mg/ml bacitracin, 0.2 m&f CaCl*, 0.03% soybean tryp- 
sin inhibitor, 0.1 mM PMSF, 1 mM benzamidine, and 5% glyc- 
erol (buffer B). An aliquot was taken for protein determination 
by the method of Lowry et al. (27) with bovine serum albumin 
METHOD 
Materials Binding of [‘251-Tyr”]SS 
Synthetic [Tyr”]SS was purchased from Universal Biologi- 
cals Ltd. (Cambridge, UK); collagenase (from Clostridium his- 
toliticum) was obtained from Serva Fine Chemicals (Tebu, 
France). Bacitracin, phenylmethylsulphonylfluoride (PMSF), 
guanosine triphosphate (GTP), 3-isobutyl- 1 -methylxanthine 
(IBMX), bovine serum albumin (BSA), Nonidet P-40, 
poly(Glu,Tyr) (4: 1 by mass), ammonium molybdate (1% in 1.32 
M HCl) were purchased from Sigma (St. Louis, MO). [y-‘*P]ATP 
was from NEN (Les Ulis, France). Sephacryl S-300 HR was from 
Pharmacia (Uppsala, Sweden). Carrier-free Na[‘2’I] (IMS 300, 
100 mCi/ml), the rabbit antibody used in the radioimmunoassay 
technique, and the cGMP kit were purchased from the Radio- 
chemical Center (Amersham, UK). This antiserum was raised in 
rabbits against SS conjugated to BSA and is specific for SS, but 
because SS constitutes the C-terminal portion of both somato- 
statin- (SS-25) and somatostatin-28 (SS-28), the antiserum 
does not distinguish between these three forms. The binding of 
SS to this antibody does not depend on an intact disulfide bond 
in the molecule, because breaking the disulfide bond by reaction 
with 0.1% mercaptoethanol(5 min boiling water bath) does not 
change peptide immunoreactivity. Cross-reactivity with other 
peptides was less than 0.5%. Cross-reaction with several SS an- 
alogues demonstrated that neither the N-terminal glycine nor the 
C-terminal cysteine residues are required for antibody binding, 
suggesting that the antigen site is directed towards the central 
part of the molecule containing the tryptophan residue. All other 
reagents were of the highest purity commercially available. 
Experimental Animals 
Male Wistar rats with an initial body weight of 200-250 g 
were used for the study. Animals were fasted for 12 h before 
surgery. Using ether anesthesia, total gastrectomy was performed 
through a midline incision by removing the entire stomach. The 
vagal trunks were preserved and continuity restored by end-to- 
end anastomosis between the esophagus and duodenum. Sham 
operation was performed by making and repairing an incision in 
the stomach. In the proglumide-treated groups, the animals re- 
ceived two times daily for 2 weeks an IP injection of proglumide 
(20 mg/kg). Proglumide was dissolved in saline solution. Post- 
operatively the rats were maintained on a 5% glucose diet for the 
first 24 h, then allowed free access to standard chow and tap 
water. These rats were sacrificed by decapitation 2 weeks after 
the intervention and the pancreas was removed and trimmed free 
of fat, connective tissues, and lymph nodes. 
Binding of [‘251-Tyr”]SS was assayed on pancreatic acinar 
membranes from Wistar rats by a modified method (12). [‘251- 
Tyr’ ‘]SS was radioiodinated by chloramine-T iodination accord- 
ing to the method of Greenwood (19). Separation of iodinated 
SS from unincorporated iodine was carried out on a Sephadex 
G-25 (fine) column equilibrated and eluted with 0.1 M acetic acid 
in BSA (0.1% w/v). The specific activity of the radioligand was 
600 Ci/mmol. 
Binding of [?-Tyr’ ‘]SS to pancreatic acinar membranes was 
carried out in a total volume of 250 ~1 in 50 mM Tris-HCl buffer 
(pH 7.4) containing 0.5 mM MgC&, 3 mM NaCl, 0.2 mM CaC12, 
0.2% (w/v) BSA, 0.5 mg/ml bacitracin, and 0.3 mg/ml soybean 
trypsin inhibitor (binding buffer). Plasma membranes (140 pg of 
protein/ml) were incubated for 90 min at 20°C with 100 pM [12’1- 
Tyr”]SS in the absence or presence of unlabeled SS. Bound and 
free ligand was separated by centrifugation at 11,000 X g for 4 
min at 4°C in a microcentrifuge. Radioactivity in the pellet was 
measured with a gamma scintillation counter. Nonspecific bind- 
ing was estimated as membrane-associated radioactivity in the 
presence of 1 ,uM SS and specific binding was calculated as the 
difference between total and nonspecific membrane-associated 
radioactivity. 
Evaluation of Radiolabeled Peptide Degradation 
To determine the extent of tracer degradation during incuba- 
tion, we measured the ability of preincubated peptide to bind to 
fresh pancreatic acinar membranes. Briefly, [‘251-Tyr”]SS (100 
PM) was incubated with pancreatic acinar membranes (140 pg 
protein/ml) for 90 min at 20°C. After this preincubation, aliquots 
of the medium were added to fresh pancreatic acinar membranes 
and incubated for an additional 90 min at 20°C. The fraction of 
the added radiolabeled peptide that specifically bound during the 
second incubation was measured and expressed as a percentage 
of the binding that was obtained in control experiments per- 
formed in the absence of pancreatic acinar membranes during the 
preincubation period. Pancreatic acinar cell membranes from all 
the groups showed a similar peptide degradation capacity and the 
values varied by no more than 9% in all the experimental groups. 
Measurement of the Particulate Guanylate Cyclase Activity 
The activity of particulate guanylate cyclase in pancreatic ac- 
inar membranes was measured using the method previously de- 
scribed (16,25) with a slight modification. The membranes (50 
pg protein/l0 ~1) were resuspended in 50 mh4 Tris-HCl, pH 7.6, 
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and used for the assay of guanylate cyclase activity. A lo-p1 
aliquot of the particulate fraction was added to tubes containing 
80 ~1 of a reaction mixture containing (final concentrations) 50 
mM Tris-HCl, pH 7.6,40 mM MnCl,, 1 mM GTP, 1 mM IBMX, 
0.01% bacitracin, and a GTP-regenerating system that consisted 
of 15 mM creatine phosphate and 20 /lg of creatine phosphoki- 
nase. After incubation at 3’7°C for 10 min with or without SS 
( 10m7- lo-” M) the reaction was stopped by the addition of 900 
~1 of 50 mM sodium acetate, pH 4.0, followed by heating at 90°C 
for 3 min. The heated incubation mixture was centrifuged at 2000 
X g for 20 min and the supematant fraction was evaporated to 
dryness. The amount of cyclic GMP generated was determined 
in the dry extract by radioimmunoassay. 
Tissue Extraction and SS R(!zdioimmunoassay 
For SS-LI measurement, the pancreata were rapidly homog- 
enized in 1 ml 2 M acetic acid using a Brinkman polytron (setting 
5, 30 s). The extracts were boiled for 5 min in an ice-chilled 
water bath, and aliquots (100 ~1) were removed for protein de- 
termination (27). The homogenates were subsequently centri- 
fuged at 15,000 x g for 15 min at 4°C and the supematant was 
neutralized with 2 M NaOH. The extracts were stored at -70°C 
until assay. The SS concentration was determined in tissue ex- 
tracts by a modified radioimmunoassay method (36), with a sen- 
sitivity limit of 10 pglml. Incubation tubes prepared in duplicate 
contained 100-/J samples of tissue extracts or standard solutions 
of O-500 pg cyclic SS diluted in phosphate buffer (0.05 M, pH 
7.2, containing 0.3% BSA, 0.01 M EDTA), 200 ~1 appropriately 
diluted anti-SS-serum, 100 ~1 freshly prepared [‘251-Tyr”]SS di- 
luted in buffer to give 6003 cpm (equivalent o 5-10 pg), in a 
final volume of 0.8 ml. All reagents as well as the assay tubes 
were kept chilled on ice before incubation for 48 h at 4°C. Bound 
hormone was separated from free hormone by the addition of 1 
ml dextran-coated charcoal (dextran T-70,0.2% w/v, Pharmacia; 
charcoal: Norit A, 2% w/v. Serva, Feinbiochemica, Heidelberg, 
Germany). Serial dilution curves for the samples were parallel 
with the standard curve. The intra- and interassay variation co- 
efficients were 6.0% and 8.8%, respectively. 
Preparation of A431 Membranes 
A431 cells were washed once with 10 m&l sodium phosphate, 
pH 7, and 150 mMNaC1 (NaCl/PJ and scraped into 10 mMNaCl/ 
P,, pH 7 (18). The cells were collected by centrifugation, sus- 
pended in 50 mM Tris-HCI, pH 7, containing 0.03% soybean 
trypsin inhibitor, 0.5 mg/ml bacitracin, and lysed by freeze- 
thawing in liquid nitrogen. The lysate was centrifuged at 170 X 
g for 5 min. The subsequent supematant was centrifuged at 
25,000 x g for 30 min. The final pellet was resuspended in the 
50 mM Tris-HCl, pH 7, containing 0.03% soybean trypsin inhib- 
itor and 0.5 mg/ml bacitracin (12). 
Preparation of Phosphorylated Poly(Glu, Tyr) 
Phosphorylated poly(Glu,Tyr) was prepared by incubating 7.2 
mg polymer with 1.5-2 rg A431 cell membranes in 50 mM 
Tris-HCl, containing 0.1 pM epidermal growth factor, 250 PM 
[Y-~~P]ATP (700 dpm/pmol), 100 fl orthovanadate, 5 mM 
MnCl*, and 0.1% Nonidet .P-40 at pH 7.5 (12). The reaction was 
allowed to proceed for 16 h at 4”C, then the mixture was sub- 
jected to gel filtration on a !jephacryl S300 HR column. Fractions 
containing the phosphorylated poly(Glu,Tyr) were pooled and 
concentrated in a Centricon- Amicon microconcentrator; IOO- 
~1 aliquots were stored at -20°C. 
Assay for Phosphotyrosine Phosphatase Activity 
PTPase activity was measured by the release of [“PIor- 
thophosphate from ‘2P-labeled poly(Glu,Tyr) in a 100-p reaction 
mixture containing 30,000 cpm “2P-labeled poly(Glu,Tyr) (final 
concentration of 0.3 PM) and 3 pg acinar pancreatic membrane 
proteins in buffer B containing 0.1% albumin. The reaction was 
allowed to proceed for 5 min at 3O”C, then stopped by the ad- 
dition of 100 ~130% trichloroacetic acid. The mixtures were kept 
on ice for 30 min, then centrifuged at 10,000 X g for 10 min to 
remove the denatured proteins. The inorganic [“‘PIphosphate lib- 
erated was extracted using the molybdate extraction procedure 
(3) and radioactivity was evaluated by liquid scintillation. The 
amount of “P, released was determined from the specific radio- 
activity of [y-‘*P]ATP used for the phosphorylation reaction. 
One unit PTPase activity was defined as the amount hat released 
1 nmol phosphate/min at 30°C from radiolabeled substrate. 
Data Analysis 
The computer program LIGAND (34) was used to analyze 
the binding data. The use of this program made it possible to 
select the receptor models that best fit a given set of binding 
data. The same program was also used to present data in the 
form of Scatchard plots (44) and to compute the values for re- 
ceptor affinity (&) and density (B,,,) that best fit the sets of 
binding data for each rat. Statistical comparisons of all the data 
were analyzed by ANOVA and the Newman-Keuls r-test. 
Means among groups were considered significantly different 
when the value was p < 0.05. Each individual experiment was 
performed in duplicate. 
RESULTS 
Two weeks following total gastrectomy, the weight of the 
pancreas increased significantly by 30% (p < 0.001) when com- 
pared to sham-operated rats. Pancreatic acinar membrane PTPase 
activity decreased (74% of control) 2 weeks after total gastrec- 
tomy, coinciding with hyperplasia of exocrine pancreatic tissue 
previously described (Fig. 1). 
Figure 2 shows that pancreatic SS-LI content 2 weeks after 
total gastrectomy was significantly lower (55% of control levels) 
than in control rats. 
The specific binding of SS to rat pancreatic acinar membranes 
increased (146% of control) after gastrectomy compared to con- 
FIG. 1. Rat pancreatic acinar membrane phosphotyrosine phosphatase 
(J?TPase) activity. Crude membranes were prepared as described in the 
Method section. FTPase activity was expressed as a percentage of control 
activity obtained with pancreatic acinar membranes from sham-operated 
rats. Control values averaged 0.13 2 0.009 nmol/mg proteinlmin. Results 
are means 2 SEM of five different experiments performed in duplicate. 
**p < 0.01 vs. respective control. Open bar: sham-operated; black bar: 
gastrectomized; speckled bar: gastrectomized plus proglumide; hatched 
bar: proglumide alone. 
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FIG. 2. Pancreatic somatostatin-like immunoreactivity (SS-LI) content 
in sham-operated (open bar), gastrectomized (black bar), gastrectomized 
plus proglumide-treated (speckled bar), and proglumide-treated (hatched 
bar) rats. Values are expressed as the mean 2 SEM in ng SS/mg protein 
for five rats per group performed in duplicate. Statistical comparison vs. 
control: **p < 0.01. 
trol conditions. When comparing the corresponding curves of 
[?-Tyr’ ‘]SS displacement by increasing concentrations of the 
unlabeled peptide (Fig. 3), the binding data were significantly 
higher in the gastrectomized group throughout the whole range 
studied. Scatchard plots of the stoichiometric binding data were 
linear and essentially parallel (Fig. 3, right panel). Interpretation 
of these data with the LIGAND computer program (34) resulted 
in the best fit for a model with one type of SS receptor. Pancreatic 
acinar membranes from gastrectomized rats exhibited significant 
increases in the maximum SS binding capacity. However, the 
corresponding K,, values remained unchanged after gastrectomy. 
The modulation of guanylate cyclase by SS was studied in 
pancreatic acinar membranes from control and gastrectomized 
rats. No significant differences were seen for basal guanylate cy- 
clase activities between the control group and the gastrectomized 
group. The capacity of SS to stimulate guanylate cyclase activity 
in control and gastrectomized rats is shown in Table 2. SS in- 
creased by twofold guanylate cyclase activity in pancreatic mem- 
branes from gastrectomized rats. 
Because the major humoral candidate for promoting pancre- 
atic hyperplasia after gastrectomy appears to be CCK (9,29), a 
group of gastrectomized rats was treated with proglumide, an 
antagonist of receptors of the gastrin/CCK peptide family to eval- 
uate whether the effects of gastrectomy on the pancreatic soma- 
tostatinergic system involved the activation of gastrin/CCK. Pro- 
glumide suppressed the inhibitory effect of gastrectomy on basal 
tyrosine phosphatase activity and SS-LI content which returned 
to control levels (Figs. 1 and 2). Furthermore, proglumide sup- 
pressed the increase of the number of SS receptors and that of 
guanylate cyclase activity induced by gastrectomy (Fig.3, Tables 
1 and 2). Proglumide was also administered to sham-operated 
control rats without producing significant differences with the 
controls in any of the studied parameters. 
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pancreatic acinar membranes because the gastrectomy-induced 
changes in the somatostatinergic system were prevented by the 
gastrin/CCK receptor antagonist proglumide. In addition, pro- 
glumide alone had no demonstrable effect on these parameters. 
Two types of receptors for the gastrin/CCK peptide family have 
been identified in pancreatic acinar cells (37,59): the CCK, re- 
ceptors, which have a much higher affinity for CCK than for 
gastrin (37); and the gastrin receptors (CCKs or CR), which have 
approximately the same affinity for CCK and gastrin (37). 
The increase in the number of SS receptors observed during 
pancreatic acinar cell hyperplasia 2 weeks after total gastrectomy 
is consistent with the view that SS may function as a negative 
regulator of pancreatic acinar cell proliferation in vivo 
(31,42,46). Pancreatic acinar cells, which do not synthesize SS 
but possess functional receptors for SS (48,58), may respond to 
SS produced in the pancreas by the D cells in the islets of Lan- 
gerhans as well as to circulating SS. 
Recently we found that exocrine pancreatic growth observed 
after proximal small bowel resection is accompanied by an in- 
crease in the number of SS receptors at 2 weeks and 1 month 
after intestinal surgery (1). In addition, in pancreatic tumor cells 
AR42J, we also observed an increase in the number of SS recep- 
tors after treatment of cells with gastrin and epidermal growth 
factor (EGF) (and with CCK, not published), which stimulate 
cell growth (55). In contrast, conditions that decrease cell growth, 
such as treatment with glucocorticoids, decrease the number of 
SS receptors on AR42J cells (56). All these results suggest that 
pancreatic acinar cell growth is associated with upregulation of 
SS receptors and this could represent a mechanism promoted by 
the cell to negatively regulate the mitogenic activity of pancreatic 
growth factors such as CCK. 
Although at least five SS receptor subtypes have been cloned 
(6), only SSTR3 (63) and SSTRS (38) are present in the islets of 
Langerhans whereas the exocrine pancreas appears to express 
only receptor subtype 2 (SSTR2) (8). Vidal et al. (55) also re- 
ported that AR42J cells expressed SSTR2 subtype strongly and 
that the gash-in- and EGF-induced increase in SS receptors was 
due to upregulation in SSTR2 subtype receptors. All these results 
suggest that the increase in SS receptor number after gastrectomy 
DISCUSSION 
Gastrectomy increased pancreatic growth (10) and this effect 
was associated with an increase in the number of SS receptors 
without alteration of affinity. 
The molecular basis for the increased number of SS receptors 
after gastrectomy is uncertain. Because growth factor-induced 
cell division is paralleled by heteroregulation of other cell surface 
receptors (7), it is possible that SS receptors are targets for het- 
erologous regulation by growth factors. Thus, the increase of SS 
receptors could be secondary to the CCK mitogenic signal 
(13,32). In this regard, the CCK receptors seem to mediate the 
action of gastrectomy on the SS receptor-effector system in the 
. 
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FIG. 3. Left panel: competitive inhibition of specific [ ‘*‘I-Tyr”]- 
somatostatin ([‘%Tyr”]SS) binding to rat pancreatic acinar membranes 
by unlabeled somatostatin. Points correspond to sham-operated (0). gas- 
trectomized (O), and gastrectomized plus proglumide (A) rats. Each 
point is the mean of five separate xperiments, each performed in dupli- 
cate. Results express the value of a pool of control groups because max- 
imal binding capacity and dissociation constant values of the control 
groups were not affected. For the sake of clarity, SEM are not represented 
but were always below 10% of mean values. Right panel: Scatchard 
analysis of the same data. The kinetic constants calculated by Scatchard 
analysis are given in Table 1. 
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TABLE 1 
EQUILIBRIUM PARAMETERS FOR SOMATOSTATIN (SS) BINDING TO 
PANCREATIC ACINAR MEMBRANES OF RATS THAT UNDERWENT A 
SHAM OPERATION, TOTAL GASTRECTOMY, TOTAL GASTRECTOMY 
PLUS PROGLUMIDE ADMINISTRATION, OR PROGLUMIDE 
ADMINISTRATION ALONE 
SS Receptors 
Groups B,,, (fmol/mg protein) 4 (mM) 
control and gastrectomized animals. The intensity of the stimu- 
latory effect of SS on guanylate cyclase activity in the gastrec- 
tomized animals is most probably related to the observed increase 
in SS receptors. These results demonstrate for the first time that 
SS stimulates membrane guanylate cyclase activity in pancreatic 
acinar cells. This effect is observed at a SS concentration that 
correlates with the affinity of SS for pancreatic SS receptors (22) 
and could be involved in the inhibitory effect of SS on pancreatic 
cell growth. 
Sham operated 
Gastrectomized 
Gastrectomized + proglumide 
Roglumide 
216 k 21 0.09 2 0.007 
316 2 30* 0.13 5 0.008 
222 2 17 0.10 r 0.006 
2i8 2 13 0.09 k 0.008 
Binding parameters were obtained by computer nonlinear regression 
analysis (LIGAND) of individual competitive binding curves. Each value 
is the mean k SEM of five separate experiments performed in duplicate. 
Comparison of means within each parameter group was by one-way 
ANOVA and Newman-Keuls tests. 
* Statistical comparison versus control: p < 0.01. 
could result, at least in part, from upregulation of the SSTR2 
subtype. 
With respect to postreceptor mechanisms, recently Viguerie 
et al. (57) and Alvaro-Alonso et al. (1) reported that the cyclic 
AMP pathway is not involved in the inhibitory effect of SS of 
pancreatic cell growth. Because recent papers support a role for 
cyclic GMP in the antiproliferative effect of SS (41), the present 
study has examined the effect of SS on guanylate cyclase activity 
in pancreatic acinar cell me:mbranes from control and gastrectom- 
ized rats. The cyclic GMP levels in pancreatic acinar membranes 
obtained in the present shady are similar to those obtained by 
Garcia-Escribano et al. (17) in mesangial cells and by Catalan 
et al. (11) in the cerebral cortex, and lower than those obtained 
by Vesely et al. (54) in the pancreas. However, the two latter 
authors measured the guanylate cyclase activity in the supema- 
tant, whereas our study and that of Garcia-Escribano et al. (17) 
measured the guanylate cyclase activity in the pellet. The present 
results show that SS increases guanylate cyclase activity signif- 
icantly in the operated rats. However, the increase is not signif- 
icant in the control rats, where it is comparable to the effect of 
proglumide alone. The increase does not appear to be due to a 
change in the number of molecules of guanylate cyclase itself 
because the activity levels were similar in membranes from both 
In addition to the intestinal mucosa, which preferentially re- 
leases SS-28 (.5), a major site of endogenous SS release is located 
within the pancreas itself, namely in the D cells of the islets of 
Langerhans. The close interaction between the islets and the ex- 
ocrine tissue appears to be at least partially mediated by an in- 
suloacinar portal system (26,35). Thus, because of the relatively 
short plasmatic half-life of SS, which has been estimated to be 
approximately l-2 min for SS and approximately 4 min for SS- 
28 (52), it seems that islet-released SS might act via the insuloac- 
inar portal system (33). Hence, despite low peripheral plasma 
levels, relatively high local plasma concentrations would be pres- 
ent around the acinar tissue and this probably has functional rel- 
evance (33). Therefore, the present study measured pancreatic 
SS-LI content. The pancreatic SS-LI levels in the control rats 
were similar to those previously reported by others (36). Gas- 
trectomy decreased pancreatic SS-LI content compared with con- 
trols. These results also agree with other experimental models of 
pancreatic growth studied by our group. Thus, two weeks after 
enterectomy, the situation is similar: increased SS receptors and 
decreased SS-LI (albeit not significant after enterectomy). Total 
gastrectomy leads to increased CCK (29) and glucagon (14) 
plasma levels compared to controls. Because it has been dem- 
onstrated that CCK and glucagon increases SS secretion (30), the 
decrease of pancreatic SS-LI levels in response to gastrectomy 
could be a consequence of increased plasma levels of both hor- 
mones. 
Cell membrane-associated tyrosine phosphatase activities 
have been characterized in various tissues (15,24). Recently, Co- 
lis et al. (12) demonstrated that the level of tyrosine phosphatase 
activity in rat pancreatic acinar cells is as high as that observed 
in some rich sources of tyrosine phosphatase such as rat spleen 
(49) or rabbit kidney (47). The control values of the present study 
are in agreement with previously reported values. Gasttectomy 
decreased tyrosine phosphatase activity. The regulation of pro- 
tein phosphorylation level in tyrosine residues is well known to 
be involved in cellular activities associated with growth and dif- 
TABLE 2 
EFFECT OF SOMATOSTATIN (SS) ON GUANYLATE CYCLASE ACTIVITY IN PANCREATIC 
ACINAR MEMBRANES OF RATS THAT UNDERWENT A SHAM OPERATION, TOTAL 
GASTRECTOMY, TOTAL GASTRECTOMY PLUS PROGLUMIDE ADMINISTRATION, 
OR PROGLUMIDE ADMINISTRATION ALONE 
- 
[SSI Sham-Operated Gastrectomized Gastrectomized + Proglumide Proglumide 
- 
0 9.3 2 1.5 9.8 2 0.9 9.5 k 0.7 9.8 -c 1.4 
1 PM 10.8 ? 0.9 11.8 ? 1.7 10.8 2 1.9 10.3 2 0.03 
IOpM 11.5 2 0.5 13.8 5 1.3 11.5 2 1.3 11.1 5 0.8 
100 pM 13.8 2 1.2 16.3 + 1.8 13.3 ? 0.6 13.6 + 1.2 
1nM 14.4 2 1.2 19.2 _f 0.4* 14.3 i 1.5 14.2 2 1.6 
1.0 nM 13.7 f 1.0 16.9 + 0.7t 13.4 2 0.2 13.5 + 1.4 
LOO nM 12.6 2 0.8 13.0 2 0.8 12.4 2 0.2 12.5 + 1.9 
- 
Values are means + SEM of determinations performed in pmol cyclic GMP/mg protein00 
min of incubation. Experiments were performed as described in the Method section. 
* t Statistical comparison vs. control: *p < 0.01, tp < 0.05. 
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ferentiation. Indeed, it has been demonstrated that CCK stimu- 
lated tyrosine kinase activity in pancreatic acini (28) and this 
stimulation is associated with the growth-promoting effect of 
caerulein (40). Conversely, SS stimulation of membrane tyrosine 
phosphatase activity has been shown to be involved in the anti- 
proliferative ffect of SS in pancreatic tumor cells (50). The de- 
crease of tyrosine phosphatase activity observed after gastrec- 
tomy is like that observed after pancreatectomy during the 
regeneration process associated with pancreatic growth (40). 
These observations uggest hat the negative regulation of tyro- 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
sine phosphatase activity may be important in the events involved 
in the pancreatic hyperplasia observed after gastrectomy. 
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